Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Application of ultrasound-guided cholecystocentesis to the evaluation of the metabolite profiling in bile of dogs and cynomolgus monkeys.

Dierks EA, Luk CE, Cai H, MacGuire J, Fox M, Smalley J, Fancher RM, Janovitz E, Foster K, Sun Q.

Pharmacol Res Perspect. 2019 May 27;7(3):e00488. doi: 10.1002/prp2.488. eCollection 2019 Jun.

2.

Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists.

Shi J, Gu Z, Jurica EA, Wu X, Haque LE, Williams KN, Hernandez AS, Hong Z, Gao Q, Dabros M, Davulcu AH, Mathur A, Rampulla RA, Gupta AK, Jayaram R, Apedo A, Moore DB, Liu H, Kunselman LK, Brady EJ, Wilkes JJ, Zinker BA, Cai H, Shu YZ, Sun Q, Dierks EA, Foster KA, Xu C, Wang T, Panemangalore R, Cvijic ME, Xie C, Cao GG, Zhou M, Krupinski J, Whaley JM, Robl JA, Ewing WR, Ellsworth BA.

J Med Chem. 2018 Feb 8;61(3):681-694. doi: 10.1021/acs.jmedchem.7b00982. Epub 2018 Jan 27.

PMID:
29316397
3.

Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode.

Jurica EA, Wu X, Williams KN, Hernandez AS, Nirschl DS, Rampulla RA, Mathur A, Zhou M, Cao G, Xie C, Jacob B, Cai H, Wang T, Murphy BJ, Liu H, Xu C, Kunselman LK, Hicks MB, Sun Q, Schnur DM, Sitkoff DF, Dierks EA, Apedo A, Moore DB, Foster KA, Cvijic ME, Panemangalore R, Flynn NA, Maxwell BD, Hong Y, Tian Y, Wilkes JJ, Zinker BA, Whaley JM, Barrish JC, Robl JA, Ewing WR, Ellsworth BA.

J Med Chem. 2017 Feb 23;60(4):1417-1431. doi: 10.1021/acs.jmedchem.6b01559. Epub 2017 Feb 9.

PMID:
28112924
4.

Rosuvastatin Liver Partitioning in Cynomolgus Monkeys: Measurement In Vivo and Prediction Using In Vitro Monkey Hepatocyte Uptake.

Morse BL, Cai H, MacGuire JG, Fox M, Zhang L, Zhang Y, Gu X, Shen H, Dierks EA, Su H, Luk CE, Marathe P, Shu YZ, Humphreys WG, Lai Y.

Drug Metab Dispos. 2015 Nov;43(11):1788-94. doi: 10.1124/dmd.115.065946. Epub 2015 Sep 4.

PMID:
26341276
5.

1-Aminobenzotriazole, a known cytochrome P450 inhibitor, is a substrate and inhibitor of N-acetyltransferase.

Sun Q, Harper TW, Dierks EA, Zhang L, Chang S, Rodrigues AD, Marathe P.

Drug Metab Dispos. 2011 Sep;39(9):1674-9. doi: 10.1124/dmd.111.039834. Epub 2011 Jun 15.

PMID:
21677062
6.

Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent.

Li HY, McMillen WT, Heap CR, McCann DJ, Yan L, Campbell RM, Mundla SR, King CH, Dierks EA, Anderson BD, Britt KS, Huss KL, Voss MD, Wang Y, Clawson DK, Yingling JM, Sawyer JS.

J Med Chem. 2008 Apr 10;51(7):2302-6. doi: 10.1021/jm701199p. Epub 2008 Mar 4.

PMID:
18314943
8.

Variable forms of soluble guanylyl cyclase: protein-ligand interactions and the issue of activation by carbon monoxide.

Vogel KM, Hu S, Spiro TG, Dierks EA, Yu AE, Burstyn JN.

J Biol Inorg Chem. 1999 Dec;4(6):804-13.

PMID:
10631613
9.

Structure-function of cytochromes P450 and flavin-containing monooxygenases: implications for drug metabolism.

Halpert JR, Domanski TL, Adali O, Biagini CP, Cosme J, Dierks EA, Johnson EF, Jones JP, Ortiz de Montellano P, Philpot RM, Sibbesen O, Wyatt WK, Zheng Z.

Drug Metab Dispos. 1998 Dec;26(12):1223-31. Review.

PMID:
9860932
10.

The catalytic site of cytochrome P4504A11 (CYP4A11) and its L131F mutant.

Dierks EA, Zhang Z, Johnson EF, de Montellano PR.

J Biol Chem. 1998 Sep 4;273(36):23055-61.

11.

The deactivation of soluble guanylyl cyclase by redox-active agents.

Dierks EA, Burstyn JN.

Arch Biochem Biophys. 1998 Mar 1;351(1):1-7.

PMID:
9500837
12.
13.

Nitric oxide (NO), the only nitrogen monoxide redox form capable of activating soluble guanylyl cyclase.

Dierks EA, Burstyn JN.

Biochem Pharmacol. 1996 Jun 28;51(12):1593-600.

PMID:
8687474

Supplemental Content

Loading ...
Support Center